IOPAMIDOL-200 (iopamidol) by Pfizer is x-ray contrast activity [moa]. Approved for radiographic contrast agent [epc]. First approved in 1997.
Drug data last refreshed 20h ago
X-Ray Contrast Activity
Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography
Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis
Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure
Renal Safety of Iopamidol Versus Iodixanol During Coronary Angiography in Diabetic Patients
Coronary MDCTA With Iopamidol Injection 370
Worked on IOPAMIDOL-200 at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.